In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From ViiV Healthcare

Drug Advertising: NAD’s Clout In Rx Disputes Rising As It Builds Ties With Social Media Platforms, FDA

National Advertising Division’s voluntary, self-regulatory process is increasingly being used to vet competitor complaints over prescription drug ads. The group now has a reporting channel to Meta, which will take down disputed claims from social media sites, and is working to demonstrate the value of self-regulation to the FDA, NAD VP Brett says.

Ad Complaints Advertising, Marketing & Sales

AIDS Group Calls Out ‘Greedy’ GSK Over HIV Drug Price In Trinidad And Tobago

Even though the cost of Tivicay is 25 times higher in Trinidad and Tobago compared to other countries in the region, GSK says that its pricing is based on several factors such as country income classification.

Generic Drugs Intellectual Property

FDA’s New PSG Batch Features GSK’s Inhalers

In its latest batch of product-specific guidances, the FDA released multiple new and revised guidances on inhalers, including several on GSK’s products such as Relenza and the Ellipta trio.

United States Guidance Documents

ViiV’s Cabenuva Could Find Niche In Non-Adherent HIV Patients

The company said results of the LATITUDE trial showed superiority for the long-acting injectable over daily oral pills in patients struggling with adherence to their HIV treatment regimens.

Clinical Trials Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals